Taipei, August 10th, 2023 — Lotus Pharmaceutical Co., Ltd. ("Lotus" or "the Company," listed on the Taiwan Stock Exchange under ticker 1795), has reported its unaudited consolidated revenue for July 2023. The company achieved an outstanding unaudited consolidated revenue of approximately NT$2.288 billion, showcasing an impressive 119% year-over-year growth. This positions July 2023 as the peak revenue-generating month of the year and the second-highest monthly revenue in the company's history.
As of the close of July, the cumulative unaudited consolidated revenue for the year-to-date has surged to NT$11.254 billion, showcasing a noteworthy 58% expansion compared to the same period last year.
Lotus Pharmaceutical's export revenue growth this month was propelled by the global distribution of Lenalidomide, including substantial shipments to the United States. Asian markets have also contributed significantly, boasting a 40% annual revenue growth for the current month.
Emphasizing its transformation from a generics-focused company to a global pharmaceutical powerhouse with a diversified portfolio, Lotus Pharmaceutical has achieved several significant milestones in recent months. Notably, the company secured its first New Chemical Entity (“NCE”) approval in Taiwan for Zepzelca® (lurbinectedin), an innovative small cell lung cancer drug licensed from Spanish partner PharmaMar. The Taiwan Food and Drug Administration (TFDA) granted Accelerated Approval for Zepzelca® in mid-July, recognizing its potential to benefit patients. Zepzelca® is set to complement Lotus' existing portfolio, joining forces with the established lung cancer medication Alimta® and the company's generic lineup featuring Vinorelbine softgel, erlotinib, and gefitinib.
Expanding its therapeutic scope beyond oncology, Lotus Pharmaceutical bolstered its CNS (Central Nervous System) portfolio by acquiring the licensing rights for the Adalarity® across 10 Asian markets from US biopharmaceutical company Corium Pharma. Adalarity® is an innovative USFDA-approved 505b (2) transdermal system of Donepezil, a leading molecule in Alzheimer. Furthermore, Lotus recently embarked on a strategic partnership with prominent US-based cardiovascular expert Amarin to introduce the innovative Vazkepa® to the Asian market. South Korea is expected to be the largest market for Vazkepa®, which is poised to synergize effectively with Korea's range of obesity products.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Enquiries:
Susan Liao, IR/PR Director
+886 2 2700 5908